| Study |
Exclusion reasons |
Rmk |
Reference |
|
Friend, 2016
|
inadequate or absent control group
|
|
Friend BMC Neurol 2016; 16:150 10.1186/s12883-016-0674-4
|
|
Holmen, 2011
|
inadequate or absent control group
|
'Natalizumab was discontinued in 149 patients (12.9%) for the following reasons: a wish to become pregnant (41 patients; 27.5%)'. 'Miscarriage were reported'
|
Holmen Mult. Scler. 2011; 17:708-19 10.1177/1352458510394701
|
|
Kleerekooper, 2018
|
inadequate or absent control group
|
|
Kleerekooper Neurol Neuroimmunol Neuroinflamm 2018; 5:e424 10.1212/NXI.0000000000000424
|
|
Schneider, 2013
|
case report or case series
|
|
Schneider Acta Neurol. Scand. 2013; 127:e1-4 10.1111/ane.12004
|
|
Illoh, 2018
|
other reason
|
|
Illoh Pharmacoepidemiol Drug Saf 2018; 27:604-611 10.1002/pds.4409
|
|
Alroughani, 2019
|
not about fetal exposure
|
|
Alroughani Mult Scler Relat Disord 2019; 34:9-13 10.1016/j.msard.2019.06.007
|
|
van Pesch, 2014
|
not about fetal exposure
|
|
van Pesch Acta Neurol Belg 2014; 114:167-78 10.1007/s13760-014-0308-9
|
|
Saraste, 2018
|
not about fetal exposure
|
|
Saraste Mult Scler Relat Disord 2018; 21:11-18 10.1016/j.msard.2018.02.008
|
|
Vukusic, 2015
|
not about fetal exposure
|
|
Vukusic Mult. Scler. 2015; 21:953-5 10.1177/1352458514554056
|
|
Portaccio, 2018
|
not relevant outcome
|
|
Portaccio Neurology 2018; 90:e832-e839 10.1212/WNL.0000000000005068
|
|
Hellwig, 2011
|
same data already obtained by other studies
|
|
Hellwig Mult. Scler. 2011; 17:958-63 10.1177/1352458511401944
|
|
Beaulieu, 2018
|
Studies without separate analysis of the considered drug/class from other drugs/class
|
EXCLUDED: Analyses performed for the group of pregnancies exposed to biologic exposed patients, without analysis for each substance : 27 were on infliximab, 7 on adalimumab, 3 on certolizumab, 2 each on natalizumab and ustekinumab, and 1 on vedolizumab.
|
Beaulieu DB Clin Gastroenterol Hepatol 2018;16:99-105 10.1016/j.cgh.2017.08.041
|
|
Bsteh, 2018
|
Studies without separate analysis of the considered drug/class from other drugs/class
|
|
Bsteh Mult. Scler. 2018; :1352458518816614 10.1177/1352458518816614
|
|
Alroughani, 2018
|
Studies without separate analysis of the considered drug/class from other drugs/class
|
|
Alroughani Neurology 2018; 90:e840-e846 10.1212/WNL.0000000000005065
|
|
Hellwig, 2010
|
Studies without separate analysis of the considered drug/class from other drugs/class
|
|
Hellwig J. Neurol. 2010; 257:580-3 10.1007/s00415-009-5376-z
|
